Literature DB >> 6313189

High-dose etoposide as single-agent chemotherapy for small cell carcinoma of the lung.

S N Wolff, D H Johnson, K R Hande, J D Hainsworth, F A Greco.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6313189

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  9 in total

1.  High-dose etoposide: from phase I to a component of curative therapy.

Authors:  Steven N Wolff; John D Hainsworth; F Anthony Greco
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

2.  Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer.

Authors:  R L Souhami; H T Hajichristou; D W Miles; H M Earl; P G Harper; C M Ash; A H Goldstone; S G Spiro; D M Geddes; J S Tobias
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma.

Authors:  I E Smith; B D Evans; S J Harland; B A Robinson; J R Yarnold; J G Glees; H T Ford
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  The effect of dose on the bioavailability of oral etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; A Johnston; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Combination high-dose etoposide and vincristine infusion.

Authors:  D V Jackson; J M Cruz; D R White; H B Muss; A R Chauvenet
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

6.  Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies.

Authors:  J D Hainsworth; S M Utley; F A Greco
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

7.  In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.

Authors:  S N Wolff; W W Grosh; K Prater; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.

Authors:  M L Slevin; S P Joel; R Whomsley; K Devenport; V J Harvey; R J Osborne; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

9.  Phase I study of vincristine and escalating doses of etoposide.

Authors:  D V Jackson; J M Cruz; P J Zekan; M E Caponera; C L Spurr; D R White; F Richards; H B Muss
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.